Processa Pharmaceuticals Inc (PCSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,691 | 5,537 | 6,308 | 6,937 | 2,897 |
| TOTAL | $1,938 | $5,671 | $6,587 | $7,154 | $3,758 |
| Non-Current Assets | |||||
| PPE Net | 4 | 4 | 4 | 4 | 5 |
| Intangibles | 1,585 | 1,145 | 0 | 0 | 0 |
| Other Non-Current Assets | 994 | 994 | 994 | 1,024 | 1,047 |
| TOTAL | $2,583 | $2,143 | $998 | $1,028 | $1,052 |
| Total Assets | $4,521 | $7,814 | $7,585 | $8,182 | $4,810 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 840 | 1,057 | 727 | 786 | 553 |
| Accrued Expenses | 1,140 | 1,180 | 1,024 | 1,263 | 681 |
| TOTAL | $1,980 | $2,236 | $1,751 | $2,075 | $1,283 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,980 | $2,236 | $1,751 | $2,075 | $1,283 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,750 | 2,660 | 2,266 | 2,014 | 475 |
| Common Shares | 0 | 0 | 5 | 4 | 1 |
| Retained earnings | -104,160 | -100,783 | -97,424 | -93,988 | -90,054 |
| Other shareholders' equity | 0 | -300 | -300 | -300 | -300 |
| TOTAL | $2,541 | $5,577 | $5,834 | $6,107 | $3,527 |
| Total Liabilities And Equity | $4,521 | $7,814 | $7,585 | $8,182 | $4,810 |